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Pompe disease is caused by glycogen accumulation due to a defi-
ciency of the lysosomal acid alpha-glucosidase enzyme by which 
it is degraded. It is a rare disease, accounting for 1:40.000 births. 
It is inherited as an autosomal recessive trait so that a couple 
presents a recurrent risk of 25% to have a child affected, at each 
pregnancy. The diagnosis could be achieved by biochemical and/
or molecular testing. Carrier detection and prenatal diagnosis 
are available when the molecular defect is known. 
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Introduction
Pompe disease, also known as glycogen storage dis-
ease type II (GSDII), is caused by glycogen accumulation 
due to a deficiency of the lysosomal acid alpha-glucosi-
dase enzyme by which it is degraded (1).
A total or partial deficiency of this enzyme causes 
lysosomal glycogen storage leading to a systemic disor-
der characterized by cardiomyopathy, muscle weakness, 
hypotonia,  and  respiratory  disorders  (1-4).  The  sever-
ity of the disease and the age of onset are related to the 
degree of enzyme deficiency. Early onset (or infantile) 
Pompe disease is the result of complete or near complete 
deficiency of GAA. Symptoms begin in the first months 
of life, with feeding problems, poor weight gain, muscle 
weakness, floppiness, and head lag. Respiratory difficul-
ties are often complicated by lung infections. The heart 
is grossly enlarged. If untreated, patients die within one 
year (3, 4).
Late onset (or juvenile/adult) Pompe disease is the 
result of a partial deficiency of GAA. The onset can be 
as early as the first decade of childhood or as late as the 
sixth decade of adulthood. The primary symptom is mus-
cle  weakness  progressing  to  respiratory  weakness  and 
death from respiratory failure, after a course lasting sev-
eral years. The heart is usually not involved. 
The standard test for conclusively diagnosing Pompe 
disease is an enzyme assay, which measures the levels of 
the GAA enzyme activity. People affected by the disease 
have lower than normal enzyme activity, usually in the 
range of 1-40% of normal levels. A diagnosis of Pompe 
disease can be confirmed by screening for the common 
genetic mutations on DNA blood samples (3-7).
Genetics 
The GAA gene (MIM# 606800) located in the hu-
man  chromosome  17q25.2-25.3  produces  an  inactive 
110 kD precursor which is transported to the lysosomal 
compartment and processed into the 95 kD intermediate 
and the fully active forms of 76 and 70 kD (1, 10). More 
than  200  mutations  in  the  GAA  gene  have  been  de-
scribed up to date (http://www2.eur.nl/fgg/ch1/pompe) 
(8-10). 
GSD II (Pompe disease) is inherited as an autosomal 
recessive trait. The most common inheritance scenario 
which results in Pompe disease is when both parents are 
carriers, usually asymptomatic. In this case, in each preg-
nancy the chances are:
1 in 4 (25%) that the child will receive two defective  •	
genes and thus inherit the disease 
2 in 4 (50%) that the child will inherit only one defec- •	
tive gene and become a carrier 
1 in 4 (25%) that the child will be completely unaf- •	
fected (Fig. 1).
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Far less common inheritance scenarios include:
If both parents have Pompe disease, then every child  •	
will inherit the disease 
If one parent has the disease and the other is a carrier,  •	
each child has a 50% chance of inheriting the disease 
and a 50% chance of being a carrier 
Historically,  children  with  classic  infantile  Pompe 
disease do not survive enough to reproduce, although the 
availability of therapy may alter this expectation through 
improved fitness of those individuals who respond to en-
zyme replacement therapy. In contrast, many individuals 
with later-onset disease survive into their 50’s and 60’s. 
The offspring of an individual with a later-onset form of 
GSD II are obligate carriers for a disease-causing muta-
tion in GAA. Furthermore, each sib of an obligate hetero-
zygote is at a 50% risk of being a carrier (11-14).
Carrier detection
In families in which a diagnosis of Pompe disease 
has been made, there is a risk that relatives may also 
have the disease or be carriers. Therefore it is important 
to test siblings of an affected child. Carrier detection can 
be achieved by two main genetic approach: biochemical 
testing, and molecular testing (7, 15, 16). 
Biochemical testing
Measurement  of  acid  alpha-glucosidase  enzyme 
activity in skin fibroblasts, muscle, or peripheral blood 
leukocytes is unreliable for carrier determination because 
of significant overlap in residual enzyme activity levels 
between obligate carriers and the general (non-carrier) 
population.
Molecular testing 
Mutation analysis is the only way to identify carriers, 
who do not have the disease, but “carry” the gene defect 
and may pass it on to their own children (15, 16). 
Genetic counseling
Genetic counseling is the process of providing indi-
viduals and families with information on the nature, inher-
itance, and implications of genetic disorders to help them 
make informed medical and personal decisions. Genetics 
clinics, staffed by genetics professionals, provide infor-
mation for individuals and families regarding the mode of 
inheritance and genetic risks to other family members as 
well as information about natural history, treatment and 
available consumer-oriented resources.
It is appropriate to offer sibs of a proband either test-
ing of GAA enzyme activity or molecular genetic testing 
(if the disease-causing mutations have been identified in 
affected family members) so that morbidity and mortal-
ity can be reduced by early diagnosis and treatment with 
Enzyme Replacement Therapy (ERT) (17, 18). Similarly 
it is appropriate to offer genetic counseling (including 
discussion of potential risks to offspring and reproductive 
options) to young adults who are affected or at risk of 
being carriers.
Carrier testing for at-risk family members and prena-
tal testing for pregnancies at increased risk are possible 
only if the disease-causing mutations in the family are yet 
identified. The optimal time for determination of genetic 
risk and discussion of the availability of prenatal testing 
is before pregnancy. 
An informed consent (IC) is requested from all in-
dividuals performing molecular genetic testing. The IC 
will contain the possibility to store the biological sample 
in a genetic biobank for possible future use. Because it 
is likely that testing methodology and our understanding 
of genes, mutations, and diseases will improve in the fu-
ture, consideration should be given to banking DNA of 
affected individuals (19). 
Prenatal diagnosis 
It can be offered, on request, to the couples who al-
ready had a child affected, or to couples at risk for an 
affected child. Prenatal diagnosis for pregnancies at in-
creased risk is possible by analysis of DNA extracted from 
fetal cells obtained by amniocentesis – usually performed 
at approximately 15 to 18 weeks’ gestation – or chorionic 
villus sampling (CVS), performed at approximately 10 
to 12 weeks’ gestation. As indicated above, we stress the 
concept that both disease-causing alleles of an affected 
Figure 1. Characteristics of an autosomal recessive in-
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family member must be identified before performing the 
prenatal testing. 
Prenatal testing is also possible by measuring GAA 
enzyme activity in uncultured chorionic villi or amnio-
cytes (biochemical testing); however molecular testing 
remains the preferred method in the case of known famil-
ial mutations (20). 
Preimplantation  genetic  diagnosis  (PGD)  may  be 
available for families in which the disease-causing muta-
tions have been identified. 
Newborn screening
It can be achieved by measuring acid α-glucosidase 
activity in dried blood spots of newborns. A large-scale 
newborn  screening  pilot  program  was  conducted  be-
tween October 2005 and March 2007 in Taiwan, involv-
ing spots of ∼45% of newborns (21). Out of the 132.538 
newborns  screened,  1093  (0.82%)  were  retested,  and 
121 (0.091%) recalled for additional evaluation. Pompe 
disease was confirmed in 4 newborns. This number was 
similar to the number of infants who received a diagno-
sis of Pompe disease in the control group (n = 3); how-
ever, newborn screening resulted in an earlier diagnosis 
of Pompe disease (<1 month old compared with 3 to 
6 months old in the control group). This was the first 
large-scale study to show that newborn screening for 
Pompe disease is feasible and allows for earlier diagno-
sis and earlier treatment. 
Conclusions and key points  
for parents 
A diagnosis of Pompe disease can be overwhelming  •	
and raise many questions. 
Genetic  counselors  are  health  care  professionals  •	
specially trained to educate families on the disease’s 
inheritance patterns and risks, as well as to support 
them through testing and family-planning decisions.
Couples should be aware that the results of prena- •	
tal testing cannot predict the age of onset, clinical 
course, or degree of disability. 
Parents must be reassured that not all infants iden- •	
tified as having low GAA activity through newborn 
screening will have Pompe disease. 
If the infant will develop Pompe disease, treatment  •	
is available which may ameliorate the clinical symp-
toms of the disorder. 
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